Scholarlink

<p><i>Komagataella</i> <i>pastoris</i> is a promising probiotic for modulating the microbiota-gut-brain axis, and growing evidence has demonstrated the relevance of this axis in the pathophysiology of neurological and psychiatric disorders, such as Alzheimer’s disease and major depressive disorder. This study investigated the ameliorated cognitive impairment and antidepressive-like effect of <i>K. pastoris</i> treatment on an AD-like mouse model induced by amyloid β<sub>1-40</sub> peptide (Aβ<sub>1-40</sub>). Behavioral tests revealed that Aβ<sub>1-40</sub> administration (400&#xa0;pmol/mouse, icv) increased immobility time in the tail suspension test, decreased spatial and working memory, and increased the time animals took to reach the chocolate cookies, and these behavioral changes were attenuated by the <i>K. pastoris</i> KM71H treatment (8 log CFU<sup>−1</sup>/mouse, ig). Biochemical changes also occurred as the applied protocol decreased reactive species and lipid peroxidation in the hippocampi and small intestine and reduced NRLP3, TLR4, Nfҡb, and IL-1β expression in the small intestine of mice. We believe that the ameliorated cognitive impairment and antidepressant effects of <i>K. pastoris</i> KM71H are due to its antioxidant activity and the modulation of the TLR4/NF-κB pathway, and our findings led us to conclude that <i>K. pastoris</i> KM71H is a promising therapeutic strategy for treating Alzheimer’s disease and major depressive disorder.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Komagataella pastoris KM71H Attenuates Cognitive Deficits and Depressive-Like Behavior by the TLR4/NF-κB Signaling Pathway in an Aβ1-40-Induced AD-Like Mouse Model

  • 期刊论文

  • 发表日期：

    2025年8月6日

查看全文
  • Paloma T. Birmann,
  • Giuliana Petiz Zugno,
  • Airton Sinott,
  • Rafael R. Rodrigues,
  • Fabricio R. Conceição,
  • Fernanda Severo Sabedra Sousa,
  • Tiago Collares,
  • Fabiana K. Seixas,
  • Lucielli Savegnago

摘要

Komagataella pastoris is a promising probiotic for modulating the microbiota-gut-brain axis, and growing evidence has demonstrated the relevance of this axis in the pathophysiology of neurological and psychiatric disorders, such as Alzheimer’s disease and major depressive disorder. This study investigated the ameliorated cognitive impairment and antidepressive-like effect of K. pastoris treatment on an AD-like mouse model induced by amyloid β1-40 peptide (Aβ1-40). Behavioral tests revealed that Aβ1-40 administration (400 pmol/mouse, icv) increased immobility time in the tail suspension test, decreased spatial and working memory, and increased the time animals took to reach the chocolate cookies, and these behavioral changes were attenuated by the K. pastoris KM71H treatment (8 log CFU−1/mouse, ig). Biochemical changes also occurred as the applied protocol decreased reactive species and lipid peroxidation in the hippocampi and small intestine and reduced NRLP3, TLR4, Nfҡb, and IL-1β expression in the small intestine of mice. We believe that the ameliorated cognitive impairment and antidepressant effects of K. pastoris KM71H are due to its antioxidant activity and the modulation of the TLR4/NF-κB pathway, and our findings led us to conclude that K. pastoris KM71H is a promising therapeutic strategy for treating Alzheimer’s disease and major depressive disorder.